Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BPMUFNASDAQ:IMVTNASDAQ:MLTXNASDAQ:MTSR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPMUFBasilea Pharmaceutica$57.70$49.79$47.50▼$57.70$759.91M0.23100 shsN/AIMVTImmunovant$15.66-1.8%$14.95$12.72▼$34.47$2.72B0.611.21 million shs1.09 million shsMLTXMoonLake Immunotherapeutics$44.21+0.4%$40.03$31.42▼$58.26$2.83B1.23383,422 shs316,243 shsMTSRMetsera$29.38-15.0%$24.39$12.30▼$37.99$3.09BN/A909,801 shs809,806 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPMUFBasilea Pharmaceutica0.00%0.00%+21.47%+9.22%+19.83%IMVTImmunovant0.00%-6.62%+12.50%-19.77%-38.73%MLTXMoonLake Immunotherapeutics0.00%-5.70%+17.39%+14.68%+2.10%MTSRMetsera0.00%+6.88%+14.72%+16.54%+2,937,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPMUFBasilea PharmaceuticaN/AN/AN/AN/AN/AN/AN/AN/AIMVTImmunovant1.5085 of 5 stars3.50.00.00.02.81.70.0MLTXMoonLake Immunotherapeutics2.0511 of 5 stars3.50.00.00.03.92.50.0MTSRMetseraN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPMUFBasilea Pharmaceutica 4.00Strong BuyN/AN/AIMVTImmunovant 2.90Moderate Buy$38.33144.79% UpsideMLTXMoonLake Immunotherapeutics 3.00Buy$78.7178.05% UpsideMTSRMetsera 3.00Buy$50.0070.18% UpsideCurrent Analyst Ratings BreakdownLatest BPMUF, MLTX, MTSR, and IMVT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2025MTSRMetseraGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$56.00 ➝ $62.006/3/2025MLTXMoonLake ImmunotherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$67.005/19/2025MLTXMoonLake ImmunotherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradePeer Perform ➝ Outperform$61.005/13/2025MLTXMoonLake ImmunotherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$78.00 ➝ $80.005/13/2025MLTXMoonLake ImmunotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$66.00 ➝ $66.004/30/2025MLTXMoonLake ImmunotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$66.00 ➝ $66.004/22/2025IMVTImmunovantUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$38.00 ➝ $17.003/20/2025IMVTImmunovantGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/20/2025IMVTImmunovantBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$38.00 ➝ $33.003/19/2025IMVTImmunovantHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$51.00 ➝ $51.003/18/2025MLTXMoonLake ImmunotherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$67.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPMUFBasilea Pharmaceutica$175.50M4.33$1.23 per share46.75($0.94) per share-61.38IMVTImmunovantN/AN/AN/AN/A$2.08 per shareN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$8.15 per shareN/AMTSRMetseraN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPMUFBasilea Pharmaceutica$11.64MN/A0.00∞N/AN/AN/AN/A8/11/2025 (Estimated)IMVTImmunovant-$259.34M-$2.74N/AN/AN/AN/A-77.94%-69.82%8/5/2025 (Estimated)MLTXMoonLake Immunotherapeutics-$36.01M-$2.30N/AN/AN/AN/A-15.54%-15.09%8/6/2025 (Estimated)MTSRMetseraN/AN/A0.00∞N/AN/AN/AN/AN/ALatest BPMUF, MLTX, MTSR, and IMVT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2025Q4 2025IMVTImmunovant-$0.72-$0.64+$0.08-$0.64N/A$0.16 million5/12/2025Q1 2025MLTXMoonLake Immunotherapeutics-$0.76-$0.63+$0.13-$0.63N/AN/A5/12/2025Q1 2025MTSRMetseraN/A-$1.03N/A-$1.03N/AN/A3/26/2025N/AMTSRMetseraN/A-$3.52N/A-$3.52N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPMUFBasilea PharmaceuticaN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/AMTSRMetseraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPMUFBasilea Pharmaceutica5.704.103.27IMVTImmunovantN/A6.046.04MLTXMoonLake ImmunotherapeuticsN/A25.5125.51MTSRMetseraN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPMUFBasilea PharmaceuticaN/AIMVTImmunovant47.08%MLTXMoonLake Immunotherapeutics93.85%MTSRMetseraN/AInsider OwnershipCompanyInsider OwnershipBPMUFBasilea PharmaceuticaN/AIMVTImmunovant5.90%MLTXMoonLake Immunotherapeutics12.02%MTSRMetseraN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBPMUFBasilea Pharmaceutica14713.17 millionN/ANot OptionableIMVTImmunovant120170.92 million159.84 millionOptionableMLTXMoonLake Immunotherapeutics264.01 million56.22 millionOptionableMTSRMetsera81105.06 millionN/AN/ABPMUF, MLTX, MTSR, and IMVT HeadlinesRecent News About These CompaniesMetsera (NASDAQ:MTSR) Shares Down 5.2% - Time to Sell?June 13 at 2:47 PM | marketbeat.comCantor Fitzgerald Forecasts Metsera FY2026 EarningsJune 13 at 3:01 AM | americanbankingnews.comMetsera (NASDAQ:MTSR) Shares Up 4.5% - Time to Buy?June 12 at 4:58 PM | marketbeat.comPromising Results Of Amylin Analogs In Obesity: Metsera Case ReviewJune 12 at 10:03 AM | seekingalpha.comMetsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i’s Positive Phase 1 ResultsJune 11, 2025 | msn.comMetsera’s Amylin Drug Looks Good in Phase 1, Shows Potential to be a Once-Monthly Obesity MedJune 11, 2025 | medcitynews.comCantor Fitzgerald Estimates Metsera FY2026 EarningsJune 11, 2025 | marketbeat.comMetsera (NASDAQ:MTSR) Shares Gap Up Following Analyst UpgradeJune 11, 2025 | americanbankingnews.comMetsera extends gains after early-stage trial data for obesity therapyJune 10, 2025 | msn.comMetsera Clears Key Benchmark, Hitting 80-Plus RS RatingJune 10, 2025 | msn.comMetsera (NASDAQ:MTSR) Shares Gap Up After Analyst UpgradeJune 10, 2025 | marketbeat.comGuggenheim Issues Positive Forecast for Metsera (NASDAQ:MTSR) Stock PriceJune 10, 2025 | marketbeat.comMetsera to Present at Goldman Sachs 46th Annual Global Healthcare ConferenceJune 10, 2025 | globenewswire.comMetsera, Inc.: Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233iJune 9, 2025 | finanznachrichten.deMetsera shares soar on positive amylin candidate trial resultsJune 9, 2025 | investing.comObesity Newcomer Metsera, Up 23%, Enters The Ring With A PunchJune 9, 2025 | msn.comMetsera Stock Climbs On Positive Results From Early Stage Trial For Investigational Weight-Loss Drug: Retail Chatter ExplodesJune 9, 2025 | msn.comMetsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss DataJune 9, 2025 | benzinga.comMetsera (NASDAQ:MTSR) Hits New 12-Month High - What's Next?June 9, 2025 | marketbeat.comMetsera rises as experimental weight-loss drug shows promise in small early-stage trialJune 9, 2025 | reuters.comMetsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233iJune 9, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBPMUF, MLTX, MTSR, and IMVT Company DescriptionsBasilea Pharmaceutica OTCMKTS:BPMUF$57.70 0.00 (0.00%) As of 06/13/2025Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.Immunovant NASDAQ:IMVT$15.66 -0.28 (-1.76%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$15.51 -0.15 (-0.95%) As of 06/13/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.MoonLake Immunotherapeutics NASDAQ:MLTX$44.21 +0.19 (+0.43%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$44.20 -0.01 (-0.01%) As of 06/13/2025 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.Metsera NASDAQ:MTSR$29.38 -5.20 (-15.04%) As of 06/13/2025 04:00 PM EasternMetsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
